Tezspire (tezepelumab or tezepelumab-ekko) is one of the available biologics for treating asthma. It's approved for people 12 years and older with severe asthma that's not controlled by other medications. Tezspire (tezepelumab) is an injection that's given under the skin once per month by a healthcare professional (HCP). There's also a prefilled pen for Tezspire (tezepelumab) that you can use at home after proper training from an HCP. Side effects aren't common but can include joint and back pain.
Add-on maintenance treatment for severe asthma in people ages 12 years and older
Tezspire (tezepelumab) is a biologic called a thymic stromal lymphopoietin (TSLP) blocker. It attaches to the TSLP protein, which is involved in causing airway inflammation in asthma. By attaching to this protein, Tezspire (tezepelumab) blocks it from working. This helps lower inflammation in your airways and better control your asthma.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Works well to prevent asthma attacks from happening and to improve your breathing
Might work better than other asthma biologics
Only given once per month
Can use in children as young as 12 years old
Given as an injection under the skin
Might be difficult for some people to administer properly
Only used as add-on therapy to other asthma medications
Hasn't been studied during pregnancy or while breastfeeding
Mark your calendar for your Tezspire (tezepelumab) injections and your appointments to see your prescriber. This can be helpful for remembering when to get your injections. And seeing your provider at follow-up visits is important for discussing how well the medication is working to manage your asthma.
It's recommended that you enroll in the Tezspire Together Program that the manufacturer offers. This program offers several resources, including an asthma symptom tracker that you can use and bring to your prescriber's office to discuss how treatment is going.
Don't take Tezspire (tezepelumab) to treat sudden asthma attacks. This medication isn't helpful for relieving asthma attacks. Make sure to keep a rescue inhaler nearby for these situations.
Before you get any vaccinations, tell your healthcare professional that you're taking Tezspire (tezepelumab). You can still get most vaccines while you're taking this medication. But you shouldn't get live vaccines because it's not known whether they work well or are safe with Tezspire (tezepelumab). An example of a live vaccine is the FluMist nasal flu vaccine.
Don't suddenly stop taking or change the dose of any of your other asthma medications while you're taking Tezspire (tezepelumab) without talking to your prescriber first, even if your asthma is getting better. This can worsen your asthma and raise your risk for certain problems. For example, suddenly lowering the dose of or stopping steroids (inhaled or by mouth) can lead to withdrawal symptoms.
Tips on how to use the Tezspire (tezepelumab) pen at home:
Before you can use Tezspire (tezepelumab) at home, your prescriber will train you on how to properly and safely inject the medication yourself. Review the instructions for use or watch the video on how to inject Tezspire (tezepelumab). Contact your prescriber or pharmacist if you have any questions.
Store unused Tezspire (tezepelumab) prefilled pens in the refrigerator. Keep them in their original package to protect them from light.
When it's time for your dose, take a Tezspire (tezepelumab) pen out of the refrigerator and place it on a flat surface for about 1 hour to warm up to room temperature. Don't warm it up any other way (e.g., microwave, under hot water) because you might damage the medication. Once the pen reaches room temperature, use it within 30 days; don't put it back in the refrigerator.
Inject Tezspire (tezepelumab) under the skin in the front of your thigh or the lower part of your stomach (2 inches away from your belly button). Never inject into a muscle, vein, or the arm.
Choose a different area of skin to inject into each time (at least 1 inch away from where you injected last time). This helps lower the risk of bruising and skin irritation. Also don't inject into skin that's tender, bruised, scaly, hard, scarred, or damaged. Don't inject through clothing.
After you inject Tezspire (tezepelumab), throw away the used pen in a sharps container or something made of heavy-duty plastic (e.g., empty milk carton, laundry detergent bottle). This helps lower the risk of needle-stick injuries. Don't throw away the pen in your trash can.
Tezspire (tezepelumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Severe allergic reactions to Tezspire (tezepelumab) are possible, including life-threatening reactions like facial swelling and anaphylaxis (closing of the throat). These reactions can happen at any time during treatment (within hours or days after injecting). Get medical attention right away if you notice dizziness, a choking sensation, difficulty breathing, nausea, swelling around your eyes, or swelling of the lips or tongue after you take Tezspire (tezepelumab).
Your body's immune response to parasitic (worm) infections might involve the same protein that Tezspire (tezepelumab) blocks. Clinical studies for Tezspire (tezepelumab) didn't include people with parasitic infections. So it's not known whether your body will respond differently to a parasitic infection while you're taking Tezspire (tezepelumab). Let your prescriber know if you have a known parasitic infection before you start Tezspire (tezepelumab) because you'll need to receive treatment for it first.
The typical dose is 210 mg injected under the skin once every month.
Add-on maintenance treatment for severe asthma in people ages 12 years and older
Add-on maintenance treatment for severe asthma
Add-on maintenance treatment for chronic rhinosinusitis with nasal polyps
Eosinophilic granulomatosis with polyangiitis (EGPA; swelling of the blood vessels)
Hypereosinophilic syndrome (HES; high eosinophils in the blood)
Moderate-to-severe allergic asthma
Chronic spontaneous urticaria (CSU) (chronic hives of unknown cause)
Lower risk of severe allergic reactions after accidental exposure to food triggers
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Amgen, Inc. (2023). TEZSPIRE- tezepelumab-ekko injection, solution [package insert]. DailyMed.
AstraZeneca. (2023). Tezspire approved for self-administration in the US with a new pre-filled pen.
AstraZeneca. (2023). TEZSPIRE instructions for use.
AstraZeneca. (2023). TEZSPIRE patient onboarding resources.
Corren, J., et al. (2017). Tezepelumab in adults with uncontrolled asthma. The New England Journal of Medicine.
Menzies-Gow, A., et al. (2021). Tezepelumab in adults and adolescents with severe, uncontrolled asthma. The New England Journal of Medicine.
Menzies-Gow, A., et al. (2022). Tezepelumab compared with other biologics for the treatment of severe asthma: A systematic review and indirect treatment comparison. Journal of Medical Economics.
Van Herck, M., et al (2018). Fatigue is highly prevalent in patients with asthma and contributes to the burden of disease. Journal of Clinical Medicine.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.